Lori F - Search Results

1

Beneficial effect of TRAIL on HIV burden, without detectable immune consequences.

Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD. Shepard BD, et al. Among authors: lori f. PLoS One. 2008 Aug 28;3(8):e3096. doi: 10.1371/journal.pone.0003096. PLoS One. 2008. PMID: 18769477 Free PMC article.

2

Long-term suppression of HIV-1 by hydroxyurea and didanosine.

Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Lori F, et al. JAMA. 1997 May 14;277(18):1437-8. JAMA. 1997. PMID: 9145714 No abstract available.

3

Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.

Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J. Lori F, et al. AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1333-8. doi: 10.1089/088922299310034. AIDS Res Hum Retroviruses. 1999. PMID: 10515148

4

Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.

Seminari E, Lisziewicz J, Tinelli C, Foli A, Lori F, Maserati R. Seminari E, et al. Among authors: lori f. Int J Clin Pharmacol Ther. 1999 Oct;37(10):514-8. Int J Clin Pharmacol Ther. 1999. PMID: 10543320 Clinical Trial.

5

Structured treatment interruptions to control HIV-1 infection.

Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Lori F, et al. Lancet. 2000 Jan 22;355(9200):287-8. doi: 10.1016/S0140-6736(99)03515-1. Lancet. 2000. PMID: 10675080

6

Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.

Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J. Foli A, et al. Among authors: lori f. Antivir Ther. 1997 Jan;2(1):31-8. Antivir Ther. 1997. PMID: 11322264 Clinical Trial.

7

Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.

Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Piccinini G, et al. Among authors: lori f. J Virol. 2002 Mar;76(5):2274-8. doi: 10.1128/jvi.76.5.2274-2278.2002. J Virol. 2002. PMID: 11836405 Free PMC article.

8

Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.

Lori F, Foli A, Maserati R, Seminari E, Xu J, Whitman L, Ravot E, Alberici F, Lopalco L, Lisziewicz J. Lori F, et al. HIV Clin Trials. 2002 Mar-Apr;3(2):115-24. doi: 10.1310/VFRX-6T7X-UQ2W-V0LK. HIV Clin Trials. 2002. PMID: 11976989 Clinical Trial.

9

Role of hydroxyurea during structured treatment interruptions.

Foli A, Seminari E, Ravot E, Lisziewicz J, Lori F. Foli A, et al. Among authors: lori f. J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):64-8. J Biol Regul Homeost Agents. 2002. PMID: 12003177 Clinical Trial.

10

Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects.

Lori F, Foli A, Lisziewicz J. Lori F, et al. J Antimicrob Chemother. 2002 Aug;50(2):155-60. doi: 10.1093/jac/dkf119. J Antimicrob Chemother. 2002. PMID: 12161394 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters